<DOC>
	<DOCNO>NCT01039675</DOCNO>
	<brief_summary>The study evaluate safety , tolerability , pharmacokinetics pharmacodynamics combination inhale GSK573719 GW64244 compare placebo , subject COPD .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Pharmacodynamics Combination GSK573719 GW642444 Subjects With COPD</brief_title>
	<detailed_description>This multicenter , randomize , double-blind , placebo-controlled , parallel group study evaluate safety tolerability combination GSK573719 ( 500mcg ) Inhalation Powder GW642444 ( 25mcg ) Inhalation Powder administer once-daily via novel dry powder inhaler ( Novel DPI ) 28 day subject COPD</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>A sign date write informed consent prior study participation Males females nonchildbearing potential 40 year age COPD diagnosis 10 packyears history great cigarette smoking Postbronchodilator FEV1/FVC ratio 0.70 less Postbronchodilator FEV1 80 % le predicted normal Current diagnosis asthma Other significant respiratory disorder besides COPD , include alpha1 deficiency Previous lung resection surgery Significant abnormalities chest xray presentation Use oral steroid , antibiotic hospitalization COPD exacerbation within 3 motnhs prior screen Any significant disease would put subject risk study participation BMI great 35 Pacemaker Significantly abnormal ECG , Holter , clinical lab finding ( include Hepatitis B C ) Cancer Allergy hypersensitivity anticholinergic inhaler excipients Diseases would contraindicate use anticholinergic Use oral corticosteroid within 6 week screen Use longacting betaagonists within 48 hour screen Use tiotropium within 14 day screen Use theophylline antileukotrienes within 48 hour screen Use shortacting bronchodilator within 4 hour screen Use investigational medicine within 30 day screen Use high dose inhale corticosteroid Use longterm oxygen therapy , CPAP NIPPV Previous use GSK573719 GW642444</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>long-acting beta2-receptor agonist</keyword>
	<keyword>Safety tolerability</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>long-acting muscarinic receptor antagonist</keyword>
	<keyword>COPD</keyword>
</DOC>